Anti-Human CD269 (TNFRSF17) (Clone CPTC-TNFRSF17-1) – Purified No Carrier Protein

TNFRSF17 synthetic peptide SLPAAL(pS)ATEIEK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0916-2B6-H1/K1 activity is directed against human TNFRSF17, peptide sequence SLPAALSATEIEK.

CPTC-TNFRSF17-1

TNFRSF17, also known as B cell maturation antigen (BCMA) or CD269, is a type III transmembrane glycoprotein that is a member of the tumor necrosis factor (TNF) receptor superfamily¹. TNFRSF17 functions as a cell-surface receptor and is involved in the regulation of B cell proliferation, maturation, and differentiation into plasma cells, and is also required for the survival of long-lived plasma cells^1,2. TNFRSF17 is more abundantly expressed on malignant plasma cells than normal plasma cells and is a novel treatment target for multiple myeloma (MM)^1,3,4, a plasma cell malignancy characterized by clonal proliferation of plasma cells within the bone marrow².

TNFRSF17 expression is upregulated during MM pathogenesis and evolution, with higher levels associated with poorer prognosis¹. The soluble form of TNFRSF17, which is derived from direct shredding of membrane-localized TNFRSF17 via γ-secretase activity, is also significantly elevated in MM patients relative to healthy individuals and is associated with worse clinical responses. As such, TNFRSF17 is a target of multiple immuno-oncology therapeutic interventions, including bispecific antibody constructs, antibody-drug conjugates, and CAR T cell therapy⁵.

EB0916-2B6-H1/K1 was generated against human TNFRSF17 in rabbit using a modified synthetic peptide, phosphorylated at S173, SLPAAL(pS)ATEIEK^6,7,8. EB0916-2B6-H1/K1 was developed for use in immuno-MRM studies and does not work in Western blotting assays. EB0916-2B6-H1/K1 also does not detect TNFRSF17 by immunohistochemistry.

TNFRSF17 is preferentially expressed on mature B lymphocytes, particularly plasmablasts and plasma cells, but also weakly on some memory B cells committed to plasma cell differentiation and plasmacytoid dendritic cells. A soluble, cleaved form is found in serum. TNFRSF17 expression is also associated with various cancers, including multiple myeloma, leukemia, lymphomas, breast invasive carcinoma, kidney renal papillary cell carcinoma, and head and neck squamous cell carcinoma. TNFRSF17 is nearly absent on naïve and memory B cells.

TNFSF13B/BLyS/BAFF, TNFSF13/APRIL, TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6

1 Yu B, Jiang T, Liu D. J Hematol Oncol. 13(1):125. 2020.
2 Trudel S, Lendvai N, Popat R, et al. Blood Cancer J. 9(4):37. 2019.
3 Ryan MC, Hering M, Peckham D, et al. Mol Cancer Ther. 6(11):3009-3018. 2007.
4 Tai YT, Mayes PA, Acharya C, et al. Blood. 123(20):3128-3138. 2014.
5 Shah N, Chari A, Scott E, et al. Leukemia. 34(4):985-1005. 2020.
6 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021
7 Whiteaker JR, Wang T, Zhao L, et al. Cancers (Basel). 13(15):3843. 2021.
8 https://research.fredhutch.org/content/dam/stripe/paulovich/files/PaulovichLab_Mab_AvailableForImmuno-MRM_11092020.pdf